Immune checkpoint blockade in cancer treatment : a double-edged sword cross-targeting the host as an &quot;innocent bystander&quot; by L. Gelao et al.
Toxins 2014, 6, 914-933; doi:10.3390/toxins6030914 
 
toxins 
ISSN 2072-6651 
www.mdpi.com/journal/toxins 
Article 
Immune Checkpoint Blockade in Cancer Treatment:  
A Double-Edged Sword Cross-Targeting the Host as an  
“Innocent Bystander” 
Lucia Gelao, Carmen Criscitiello, Angela Esposito, Aron Goldhirsch and  
Giuseppe Curigliano * 
Division of Early Drug Development for Innovative Therapies, Istituto Europeo di Oncologia,  
Via Ripamonti 435, Milano 20141, Italy; E-Mails: lucia.gelao@ieo.it (L.G.);  
carmen.criscitiello@ieo.it (C.C.); angela.esposito@ieo.it (A.E.); aaron.goldhirsch@ieo.it (A.G.) 
* Author to whom correspondence should be addressed; E-Mail: giuseppe.curigliano@ieo.it;  
Tel.: +39-02-57489788; Fax: +39-02-94379224. 
Received: 27 November 2013; in revised form: 21 January 2014 / Accepted: 18 February 2014 /  
Published: 3 March 2014 
 
Abstract: Targeted immune checkpoint blockade augments anti-tumor immunity and 
induces durable responses in patients with melanoma and other solid tumors. It also 
induces specific “immune-related adverse events” (irAEs). IrAEs mainly include 
gastrointestinal, dermatological, hepatic and endocrinological toxicities. Off-target effects 
that arise appear to account for much of the toxicity of the immune checkpoint blockade. 
These unique “innocent bystander” effects are likely a direct result of breaking immune 
tolerance upon immune check point blockade and require specific treatment guidelines that 
include symptomatic therapies or systemic corticosteroids. What do we need going forward 
to limit immune checkpoint blockade-induced toxicity? Most importantly, we need a better 
understanding of the roles played by these agents in normal tissues, so that we can begin to 
predict potentially problematic side effects on the basis of their selectivity profile. Second, 
we need to focus on the predictive factors of the response and toxicity of the host rather 
than serially focusing on individual agents. Third, rigorous biomarker-driven clinical trials 
are needed to further elucidate the mechanisms of both the benefit and toxicity. We will 
summarize the double-edged sword effect of immunotherapeutics in cancer treatment. 
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1. Introduction 
The primary concept of cancer immunotherapy is to enable the immune system to detect neoplastic 
growth and to either prevent carcinogenesis and/or reject transformed cells with a potential for 
malignant tumor growth. Immunotherapy in cancer, and, especially, the implementation of active 
immunotherapy into clinical trials (specifically in the adjuvant setting), has been a largely frustrating 
experience over the last two decades. Recent advances in clinical and basic research led to a new 
understanding of the immunology and heterogeneity of cancer. Chemotherapy and targeted treatments 
can modulate the immune system. Immune response to cancer is a dynamic process that can lead to the 
rejection of cancer, but can also have regulatory effects that promote tumor growth. The concept  
of immunoediting in cancer has profoundly changed our current knowledge about the long-term 
efficacy of chemotherapy and radiotherapy [1]: in fact, treatments formally believed to be highly 
immunosuppressive can potentially enhance immune response. 
2. Role of Immunotherapy in Cancer Treatment 
Evading immune destruction should be considered an emerging hallmark of cancer. The knowledge 
of the underlying principles of tumor biology and immunology, enhanced by recent insights into the 
mechanisms of immune recognition, regulation and tumor escape, has provided new approaches for 
cancer immunotherapy [2]. Highly immunogenic cancer cells can be eliminated in immunocompetent 
hosts as a result of the ‘‘immunoediting’’ process. Weakly immunogenic variants can grow and 
generate solid tumors [1]. 
A variety of tumor infiltrating cells, including regulatory T-cells (Tregs), myeloid-derived 
suppressor cells (MDSC) and activated (type 2) macrophages (M2), are involved in the modulation of 
immune responses in cancer patients [3]. For example, an increased number of Tregs was found in 
blood and in the tumor microenvironment of patients affected by different tumors: it was demonstrated 
that Tregs suppress T-cell response and natural killer (NK) cell proliferation and function, thus 
interfering both with acquired and innate immunity [4]. The prognostic significance of tumor 
infiltration by Tregs is yet unclear. In some tumor types, including ovarian and breast cancer, an 
increased number of intratumoral Tregs is associated with bad prognosis [5,6], whereas in other types, 
such as colorectal cancer and head and neck carcinoma tumor, infiltration by Tregs frequently 
correlates with improved disease outcome [7,8]. 
Therefore, cancer tries to evade the immune system by exploiting a series of immune escape 
mechanisms that were developed to avoid autoimmunity (mechanisms of tolerance). Among these 
mechanisms are the hijacking of immune cell-intrinsic checkpoints that are induced on T-cell 
activation. The blockade of one of these checkpoints such, as cytotoxic T-lymphocyte-associated 
antigen 4 (CTLA-4) [9] or the programmed death 1 (PD-1) receptor, recently provided the first 
evidence of the activity of an immune-modulation approach in the treatment of solid tumors [10,11]. 
Several efforts have also been made in recent years to identify other molecules involved in the immune 
response to develop a wide variety of potential immunotherapeutic targets for the treatment of  
cancers [12]. Some approaches use antibodies against a specific tumor-associated antigen (TAA) or  
T-lymphocytes taken from cancer patients and then modified with genes encoding receptors that 
recognize cancer-specific antigens (passive immunotherapy) [13,14]. Other approaches employ TAAs 
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that are injected into the host with dendritic cells (DCs) or adjuvants to develop a specific anti-tumor 
immune response (active immunotherapy) [15]. The majority of these approaches have provided 
encouraging results, inducing a detectable tumor-antigen-specific immunity and, in some case, clinical 
benefit. However, the potent and specific immune responses generated by some of these 
immunotherapeutic strategies did not obtain a prolonged objective responses in cancer patients. 
Several reasons may explain these unsatisfactory results and the difficulty to develop effective 
immunotherapies in controlling cancer. One reason might be that many antigens identified as 
therapeutic targets in human cancer are self or “self-altered” antigens, which are aberrantly expressed 
or overexpressed on transformed cells. In order to develop a specific and long-lasting immune 
response and increase the success of immunotherapy, it might be useful to disrupt the  
immune-regulatory mechanisms that contribute to tumor tolerance [16]. Given these observations, 
several modalities have been developed to target immune suppressive components, such as depletion 
of Treg [17,18], inhibition of immune suppressive metabolites, including indolamine-2,3-dioxygenase 
(IDO), arginase and inducible nitric oxide synthetase (iNOS) [19], or targeting immune inhibitory 
molecules, such as signal transducer and activator of transcription 3 (STAT-3) [20]. The immune 
checkpoint blockade targeted agents, such as ipilimumab, anti-CTLA-4, anti-PD-1 receptor or  
anti-programmed death-1 ligand-1 (PD-L1), can be considered really breakthrough drugs in the 
treatment of solid tumors, and the use of checkpoint blockade antibodies has generated great 
enthusiasm [21]. Finally, agonistic monoclonal antibodies targeting co-stimulatory molecules, 
including cluster of differentiation (CD)-40, CD-134 and CD-137, have been developed and evaluated 
in Phase I clinical trials for solid and hematological malignancies [22,23]. 
3. Mechanisms of Action of Immunomodulators 
The activity of a T-cell is regulated by the expression of various molecules and a variety of  
immuno-modulatory signals, both co-stimulatory and co-inhibitory, that are required to generate an 
optimal antigen-specific immune response [14]. 
In the ‘‘two-signal’’ model of T-cell activation, antigen-specific T-cell activation needs two signals 
between T-cells and antigen presenting cells (APCs): the first signal involves the presentation of an 
antigen to a T-cell receptor (TCR) by a major histocompatibility complex (MHC) molecule on APCs.  
To complete T-cell activation, a second signal is needed and requires the interaction of the CD28 
receptor on T-cells to B7 co-stimulatory molecules (B7-1 and B7-2) on APCs [24]. Besides these  
co-stimulatory signals, negative regulators of T-cell immunity, including CTLA-4 and PD-1, are 
needed in order to prevent inappropriate T-cell activation, resulting in autoimmunity. Preclinical data 
suggest that the blockade of these co-inhibitory molecules or enhancement of co-stimulatory molecules 
can amplify T-cell responses against tumors [21]. Figure 1 summarizes the mechanisms of activation 
of the immune system following exposure to tumor antigens. 
CTLA-4 is a member of the CD28:B7 immunoglobulin superfamily, and it is normally expressed at 
low levels on the surface of naive effector T-cells and Tregs [25]. After stimulation of a naive T-cells 
through the TCR, CTLA-4 is upregulated and competes with CD28 for B7 and, finally, leads to 
suppression of T-cell activity [26]. The induction of tolerance in antigen specific T-cells can be 
promoted also by other mechanisms, such as direct inhibition of TCR signals, reduction of IL-2 
Toxins 2014, 6 917 
 
 
production and downregulation of IL-2 receptor expression [27,28]. Moreover, some studies suggest 
that the antitumor effect of CTLA-4 blockade might depend on the depletion of Treg [29], as 
demonstrated in a model of mouse melanoma, in which both the enhancement of T effector cell 
function and inhibition of Treg activity through the blockade of CTLA-4 led to a strong  
antitumor response [25]. 
Figure 1. The ‘‘two-signal’’ model of T-cell activation, first requiring the interaction of  
T-cell receptor (TCR) with a major histocompatibility complex (MHC) molecule expressed 
by antigen presenting cells (APCs). To complete T-cell activation, the interaction of the 
CD28 receptor on T-cells with B7 co-stimulatory molecules (B7-1 and B7-2) on APCs is 
necessary. This phase occurs primarily within the lymph nodes. To prevent inappropriate 
T-cell activation, negative regulators of T-cell immunity, including CTLA-4 and PD-1, are 
required. CTLA-4 competes with CD28 for the interaction with B7, and it is upregulated 
shortly after T-cell activation. Anti-CTLA-4 antibodies, such as ipilimumab and 
tremelimumab, block CTLA4 and, thereby, enhance antitumor activity. The PD-1 
inhibitory receptor plays an important role in modulating T-cell activity in the peripheral 
tissues during the effector phase. The ligation of PD-1 with PD-L1 causes the negative 
regulation of T-cells in the tumor microenvironment. Blockade with antibodies of PD-1 or 
PD-L1 (e.g., nivolumab and MK-3475) results in the activation of T-cells. TAA,  
tumor-associated antigen; NK, natural killer. 
 
In addition to CTLA-4, PD-1 is a key immune checkpoint protein and represents a promising 
immunotherapeutic target. It is a co-inhibitory molecule expressed on chronically stimulated T-cells, 
as well as Tregs, activated B-cells and natural killer (NK) cells [30]. PD-1 appears to play a crucial 
function in modulating T-cell activity in peripheral tissues through interaction with its ligands, PD-L1 
(B7-H1) and PD-L2 (B7-DC) [10]. PD-L1 and, to a lesser extent, PD-L2 are expressed on many 
hematologic and non-hematologic human tumors [31]. The evidence of the involvement of the  
PD-1/PD-L1 pathway in immunosuppression mechanisms arises from experimental models showing 
that mice with a genetic deficiency of PD-1 present enhanced immunity with phenotypes characterized 
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by autoimmune cardiomyopathy and a lupus-like syndrome [32,33]. In human cancer, the interaction 
between PD-1 and its ligand, PD-L1, leads to the suppression of T-cell activity, resulting in immune 
evasion by cancer cells [25]. Since monoclonal antibodies can block this interaction, they have been 
evaluated as a strategy to augment the immune response. 
Beside the CTLA-4 and PD-1/PD-L1 molecules, other immune-modulatory targets have been 
identified, such as killer immunoglobulin-like receptors (KIRs) expressed by NK cells [34] and  
the TNF super family co-stimulatory molecules, including CD-40, CD-134 and CD-137 [35,36]. CD40  
is expressed by immune cells and by various type of cancer cells. Some studies report that CD40 
expression on certain tumor cell types has been implicated in pro-apoptotic and anti-proliferative 
activity, suggesting a potential use of this target in anticancer treatment. Similarly CD137, expressed 
by activated T-cells, dendritic and NK cells, seems to enhance T-cell proliferation and IL-2 secretion 
and might be used to increase immune activity to eliminate tumors. 
4. Clinical Trials with Immune Checkpoint Blockade Targeted Agents 
Based upon the results of preclinical studies that support the evidence of the involvement of these 
molecules in immune control, various antibodies blocking CTLA-4, PD-1 or PD-L1 or other immune 
targets are actually used in clinical practice. 
Ipilimumab (Yervoy®) is a monoclonal antibody (mAb) designed to block CTLA-4, thereby 
preventing the development of tolerance and augmenting anti-tumor responses [37]. This drug was 
evaluated in several Phase I/II/III clinical trials and in different tumor types, including prostate cancer, 
non-small cells lung cancer (NSCLC), renal carcinoma and pancreatic cancer [38–41]. The efficacy 
and safety of ipilimumab was most frequently studied in melanoma. The study that led to the approval 
of ipilimumab by the U.S. Food and Drug Administration (FDA) was a three-arm randomized trial 
comparing the combination of ipilimumab with gp100 peptide vaccine versus gp100 vaccine alone 
versus ipilimumab alone in 676 patients affected by metastatic melanoma who had failed prior  
therapy [42]. The median overall survival (OS) was increased from 6.4 months to 10.0 months with the 
addition of ipilimumab to gp100 vaccine (p < 0.0001), and also, long-term survival rates improved. 
Severe or potentially life threatening (Grade 3 or 4) adverse events occurred in 10%–15% of patients 
treated with ipilimumab and in 3% of those treated with gp100 alone. Fourteen deaths related to the 
study drugs (2.1%) were recorded. In a subsequent Phase III trial, 502 patients with metastatic 
melanoma that was previously untreated were randomly assigned to dacarbazine with ipilimumab or 
dacarbazine with placebo. OS was significantly increased in patients assigned to the ipilimumab arm 
compared to the placebo arm (median 11.2 versus 9.1 months) [9]. Grade 3 and 4 adverse events 
occurred in 56.3% of patients in the ipilimumab plus dacarbazine group compared with 27.5% treated 
with dacarbazine and placebo. No drug-related deaths were reported in the ipilimumab group. The 
European Organization for Research and Treatment of Cancer (EORTC) and the Eastern Cooperative 
Oncology Group (ECOG) have designed two clinical trials National Clinical trial(NCT)00636168 and 
NCT01274338, respectively) to evaluate the efficacy of this drug in the adjuvant setting of melanoma. 
Moreover, combinations of ipilimumab with other therapeutic approaches, such as chemotherapy, 
immunotherapy, including dendritic cell vaccine, or radiotherapy are currently under investigation in 
several clinical trials [43]. 
Toxins 2014, 6 919 
 
 
The clinical activity of another CTLA-4-blocking antibody, tremelimumab, was also investigated. 
Based on the encouraging response obtained in Phase I/II trials [44,45], a Phase III trial was conducted 
in which previously untreated patients with melanoma were randomly assigned to either tremelimumab 
or chemotherapy. The results of this study demonstrated durable responses in patients treated with 
tremelimumab despite the endpoint of improved OS not being reached [46]. Tremelimumab has also 
been studied in Phase II trials of patients with metastatic colorectal, gastric, esophageal cancers and 
NSCLC, alone or in combination with other anticancer therapies [47–49]. 
Given the success of targeting this first immune inhibitory checkpoint, Phase I/II studies of mAb 
against PD-1 and PD-L1 have been performed. Nivolumab, an anti-PD-1 mAb, was evaluated in a 
Phase I/II study in 296 patients with pretreated NSCLC, prostate cancer, renal cell carcinoma, 
colorectal cancer and melanoma [10]. Clinical responses were recorded in around 30% of the 
melanoma patients, but also, among patients with renal cell carcinoma and NSCLC, such response 
were seen. At the 2013 American Society of Clinical Oncology (ASCO) annual meeting, the long-term 
follow-up data of patients treated with nivolumab were presented, confirming an excellent durability of 
nivolumab-induced responses and showing 61% one-year and 44% two-year survival rates in 
melanoma patients [50]. The adverse effects were less frequent than those observed in patients treated 
with ipilimumab. The combination of anti-PD1 and anti-CTLA4 was evaluated also in 53 patients, 
resulting in an improved response rate, without additional toxicity [51]. Lambrolizumab is another 
anti-PD-1 mAb, which was tested in 135 patients with advanced melanoma. The response rate in patients 
treated with this agent was 38%, and the responses were durable in the majority of patients [52]. 
Clinical activity has been observed also with different anti-PD-L1 drugs [11]. Unlike PD-1 antibodies, 
PD-L1 antibodies spare potential interactions between PD-L2 and PD-1, but additionally block 
interactions between PD-L1 and CD80, even if the therapeutic significance of these interactions is still 
unclear [53]. In a Phase 1 trial, anti-PD-L1 therapy produced durable tumor regression (objective 
response rate: six to 17%) in patients with metastatic NSCLC, melanoma, renal-cell cancer and ovarian 
cancer; Grade 3 or 4 adverse events occurred in only 9% of patients [11]. Many anti-PD-L1 agents are 
currently being investigated, such as BMS-936559 and MPDL3280A, and preliminary data indicate 
that these mAb are safe in multiple tumor types [54,55]. 
5. Clinical Trials with Immune-Stimulatory and Immune-Suppressor Molecules 
Finally, several strategies were designed to target co-stimulatory molecules and immune-suppressor 
metabolites. Small molecule inhibitors blocking IDO have shown efficacy in preclinical models [56], 
whereas Phase I/II clinical trial are testing strategies to deplete Tregs through the blockade of their 
CD25 surface receptor. Denileukin diftitox, an IL-2-diptheria toxin fusion protein, was developed as a 
therapeutic strategy for cutaneous T-cell lymphoma, and clinical responses have been seen also in 
melanoma [57]. mAbs against CD25, such as daclizumab, were explored in the clinical setting, and 
early results indicated durable reduction in Treg numbers after a single dose of daclizumab [58]. In a 
Phase I trial, BMS-663513, a fully human anti-CD137 agonist mAb, was studied with encouraging 
results in patients affected by solid tumors, including melanoma ovarian, prostate cancer and  
NSCLC [35]. Instead, a Phase II trial conducted in patients with metastatic melanoma was stopped,  
due to an unexpected high incidence of Grade 4 hepatitis [59]. Other clinical trials were performed to 
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assess the efficacy of mAb that targets CD40 in hematologic and solid tumor [22,36]. Recently, the 
efficacy of mAb against OX40 was investigated, which is a costimulatory receptor expressed primarily 
on activated CD4+ and CD8+ T-cells. A Phase I clinical trial was performed in patients with advanced 
cancer, and therapy with anti-OX40 mAb showed an acceptable toxicity profile and the regression of 
at least one metastatic lesion in 12 of 30 patients, although there were no responses according to the 
Response Evaluation Criteria In Solid Tumors (RECIST) criteria [60]. Table 1 summarizes the major 
clinical trials with immunomodulators in solid and hematological malignancies. 
Table 1. Major clinical trials with immunomodulators in solid and hematological malignancies. 
Study 
drug 
National 
Clinical Trial 
(NCT) Number 
Disease Therapy Phase 
Primary 
Endpoint 
Anti-CTLA-4 antibodies 
Ipilimumab      
 NCT01489059 Melanoma IL-21 + Ipilimumab I Safety 
 NCT01676649 Melanoma Ipilimumab + Carboplatin + Paclitaxel II Safety 
 NCT01498978 Prostate Cancer 
Ipilimumab + Androgen Suppression 
Therapy 
II Efficacy 
 NCT01896869 Pancreatic cancer FOLFIRINOX Followed by Ipilimumab II Efficacy 
 NCT01363206 Melanoma 
Granulocyte Macrophage-Colony 
Stimulating Factor + Ipilimumab 
II Safety/Efficacy
 NCT01988077 Melanoma Adoptive T-Cell Transfer + Ipilimumab II Safety/Efficacy
 NCT01856023 Melanoma IL-2 + Ipilimumab III Safety/Efficacy
 NCT01822509 
Hematologic 
Malignancies 
Ipilimumab After Allogeneic 
Hematopoietic Cell Transplantation 
I Safety 
 NCT01611558 Ovarian Cancer Ipilimumab II Safety 
 NCT01450761 Small Cell Lung Cancer Etoposide + Platinum +/− Ipilimumab III Efficacy 
 NCT01604889 Melanoma Ipilimumab +/− INCB024360 I/II Safety/Efficacy
 NCT01024231 Melanoma BMS-936558 + Ipilimumab I Safety/Efficacy
 NCT01832870 Prostate Cancer Sipuleucel-T + Ipilimumab I Safety/Efficacy
 NCT01524991 Urothelial Carcinoma Gemcitabine, Cisplatin + Ipilimumab II Safety/Efficacy
 NCT01285609 
Squamous Non-Small 
Cell Lung Cancer 
Paclitaxel + Carboplatin +/− Ipilimumab III Efficacy 
 NCT01565837 Melanoma 
Ipilimumab + Stereotactic Ablative 
Radiation Therapy 
II Safety/Efficacy
 NCT01689974 Melanoma 
Ipilimumab vs. Ipilimumab + 
Radiotherapy 
II response rates
 NCT01750983 Advanced Cancers Ipilimumab + Lenalidomide I Safety/Efficacy
 NCT01489059 Melanoma IL-21/Ipilimumab I Safety 
 NCT01740297 Melanoma 
Ipilimumab +/− Talimogene 
Laherparepvec 
I/II Safety/Efficacy
 NCT01274338 Melanoma 
Ipilimumab or High-Dose Interferon 
Alfa-2b 
III Efficacy 
 NCT01738139 Advanced Cancers Ipilimumab +/− Mesylate I Safety/Efficacy
 NCT01827111 Melanoma Abraxane + Ipilimumab II Safety/Efficacy
 NCT01767454 Melanoma Ipilimumab + Dabrafenib +/− Trametinib I Safety 
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Table 1. Cont. 
Study drug NCT Number Disease Therapy Phase 
Primary 
Endpoint 
Anti-CTLA-4 antibodies 
Ipilimumab      
 NCT01860430 
Cancer of Head and 
Neck 
Cetuximab + Radiotherapy + Ipilimumab I Safety/Efficacy
 NCT01673854 Melanoma Vemurafenib Followed by Ipilimumab II Safety 
 NCT01608594 
Melanoma 
(Neoadjuvant) 
Ipilimumab + IFN-α2b II Safety/Efficacy
 NCT01590082 Melanoma 
Doxycycline, Temozolomide + 
Ipilimumab 
I/II Safety/Efficacy
 NCT01711515 Cervical Cancer Chemoradiation Therapy + Ipilimumab I Safety 
 NCT01810016 Melanoma NY-ESO-1 Vaccine + Ipilimumab I Safety/Efficacy
 NCT01896999 Hodgkin Lymphoma Ipilimumab and Brentuximab Vedotin I Safety 
 NCT01473940 Pancreatic Cancer Ipilimumab and Gemcitabine I Safety 
 NCT01729806 B-Cell Lymphoma Ipilimumab + Rituximab I Safety 
 NCT01331525 Small Cell Lung Cancer Ipilimumab + Carboplatin + Etoposide II Efficacy 
 NCT00836407 Pancreatic Cancer Ipilimumab +/− Vaccine Therapy I Safety 
 NCT01643278 
Gastrointestinal Stromal 
Tumors or Other 
Sarcomas 
Dasatinib and Ipilimumab I Safety 
 NCT00636168 Melanoma Melanoma vs. placebo III Efficacy 
Tremelimumab 
 NCT01843374 Mesothelioma Tremelimumab vs. Placebo II Safety/Efficacy
 NCT01853618 Liver Cancer Tremelimumab + Chemoembolization I Safety 
 NCT01975831 Solid Tumors MEDI4736 + Tremelimumab I Safety 
 NCT01103635 Melanoma Tremelimumab + CP-870,893 I Safety 
Anti-PD-1 antibodies 
Nivolumab 
 NCT01783938 Melanoma Ipilimumab followed by Nivolumab II Safety 
 NCT01454102 
Non-small Cell Lung 
Cancer 
Nivolumab + Chemotherapy or As 
Maintenance Therapy 
I Safety 
 NCT01928394 Solid Tumors Nivolumab or Nivolumab + Ipilimumab I/II Efficacy 
 NCT01642004 
Squamous Cell  
Non-small Cell Lung 
Cancer 
Nivolumab vs Docetaxel III Efficacy 
 
NCT01844505
NCT01927419 
Melanoma 
Nivolumab or Nivolumab + Ipilimumab 
or Ipilimumab 
III/II Efficacy 
 NCT01668784 Renal Cell Carcinoma Nivolumab vs. Everolimus III Efficacy 
 NCT01968109 Solid Tumors Anti-LAG-3 +/− Anti-PD-1 I Safety 
 NCT01592370 Hematologic Malignancy Nivolumab I Safety 
 NCT01721772 Melanoma Nivolumab vs. Dacarbazine III Efficacy 
Anti-CTLA-4 antibodies 
Ipilimumab      
 NCT01629758 Solid Tumors IL-21+ Nivolumab I Safety 
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Table 1. Cont. 
Study drug NCT Number Disease Therapy Phase 
Primary 
Endpoint 
MK-3475 
 NCT01295827 Solid Tumor MK-3475 I Safety/Efficacy
 NCT01840579 Solid Tumor MK-3475 + chemotherapy I Safety 
 NCT01905657 Non-Small Cell Lung Cancer MK-3475 vs. Docetaxel II/III Safety/Efficacy
 NCT01866319 Melanoma MK-3475 vs. Ipilimumab III Safety/Efficacy
 NCT01848834 Solid Tumor MK-3475 I Safety/Efficacy
Anti-PD-L1 antibodies 
BMS-936559 
 NCT00729664 Cancer BMS-936559 I Safety 
MPDL3280A      
 NCT01633970 Solid Tumors 
MPDL3280A + Bevacizumab +/− 
Chemotherapy 
I Safety 
 NCT01656642 Melanoma MPDL3280A + Vemurafenib I Safety 
 NCT01846416 Non-small Cell Lung Cancer MPDL3280A II/III Safety/Efficacy
 NCT01903993 Non-small Cell Lung Cancer MPDL3280A vs. Docetaxel II Safety/Efficacy
Other immunomodulators 
BMS-986015 (Anti-KIR) 
 NCT01750580 Cancer BMS-986015 + Ipilimumab I Safety 
Daclizumab (anti CD25) 
 NCT01468311 Hodgkin’s Lymphoma Daclizumab I/II Safety/Efficacy
 NCT01307618 Melanoma 
Vaccine +/− IL-12 Followed by 
Daclizumab 
II Safety/Efficacy
BMS-663513 (CD137 agonist) 
 NCT01471210 
Non-Hodgkin’s 
Lymphoma/Solid Tumors 
BMS-663513 I Safety 
 NCT01775631 Non-Hodgkin’s Lymphoma BMS-663513 + Rituximab I Safety 
6. Immune-Related Toxicity of Immune Checkpoint Inhibitors 
Toxicity is a major issue for the new cancer immunotherapy. Ipilimumab and other immunomodulatory 
drugs have been associated with several immune-related adverse events (irAEs); most of them related 
to the infiltration of highly-activated CD4 and CD8 T-cells and the increased production of 
inflammatory cytokines in normal tissues [61]. In fact, skin and gut biopsies performed in the sites of 
irAEs showed that the involved organs were infiltrated with both CD4+ and CD8+ T-cells. Elevated 
levels of inflammatory cytokines released by activated T-cells were reported in the sera of these 
patients [59]. This observation, beside the evidence of the rapid resolution of some irAEs after the use 
of the anti-tumor necrosis factor (anti-TNF) antibody, infliximab, suggested that cytokines may be 
associated with the development of toxicities related to the use of these agents. 
Animal models and clinical trials support a role for CTLA-4 blockade in breaking the tolerance to  
both human cancer antigens and self-antigens. CTLA-4 blockade in murine cancer models increased 
the regression of immunogenic tumors [62], but caused depigmentation, thus implying a role for 
CTLA-4 not only in tumor antigenicity, but also in the suppression of autoimmunity [63]. Histological 
evaluation of depigmented lesions revealed the infiltration of polymorphonuclear cells and deposition 
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of antibody. Furthermore, CTLA-4-deficient mice died early, about one month after birth, due to 
lympho-proliferative disease and autoimmunity [64,65]. Other studies have demonstrated that  
anti-CTLA-4 in animal models led to T-cell-associated autoimmune toxicities, including diabetes, 
demyelinating lesions, encephalomyelitis and colitis [66–68]. The combination of CTLA-4 blockade 
and an irradiated tumor cell vaccine in a prostate cancer mouse model elicited a potent antitumor 
response, but prostatitis accompanied by the destruction of epithelium were also reported, indicating 
that the immune response was, at least in part, directed against normal prostate antigens [69]. Thus, 
these autoimmune effects suggest that the immune targets for these responses can be represented by 
normally expressed differentiation antigens and that CTLA-4 blockade is able to break peripheral 
immune tolerance. 
Phan et al. reported that the use of anti-CTLA-4 antibody to metastatic melanoma patients resulted 
in objective cancer regression in three of 14 patients and autoimmune manifestations in six of 14 
patients (43%) [70]. In a subsequent study, same authors hypothesized that in patients with metastatic 
melanoma, CTLA-4 blockade might enhance the antitumor effect of IL-2, since IL-2 stimulates T-cell 
growth, but has also been implicated in the expansion of Tregs that express cell-surface CTLA-4. 
Twenty five percent of responders experienced Grade 3/4 autoimmunity attributable to anti-CTLA-4 
therapy. In comparison to previous experience, in this study, the incidence of autoimmunity was 
decreased, maybe due to the supportive effect of IL-2 on Treg cell activation and proliferation [71]. 
The most common irAEs involve gastrointestinal tract, skin, liver and endocrine system [72]. These 
effects are reported in up to 60% of patients treated with ipilimumab, with severe toxicities (Grade 3 or 4) 
in about 10%–15% of patients [42]. They can appear at various times after anti-CTLA-4 treatment. 
The average timelines for irAEs are 2–3 weeks for dermatologic events, 6–7 weeks for gastrointestinal 
and hepatic events and nine weeks for endocrine events [73]. The presentation of irAEs can vary from 
insidious to sudden and can be confused with other known autoimmune conditions. Usually, irAEs 
were reversible, but in rare cases, they may be severe and life threatening. The most common 
dermatologic toxicities include maculopapular, erythematous rash or pruritus. Vitiligo can also be seen 
and is considered a positive prognostic factor in patients with melanoma, as it signals an immune 
attack on melanocytes. Frequently, irAEs involved gastrointestinal tract. Grade 3/4 diarrhea/colitis  
was the most frequently observed serious adverse event in clinical trials. Among 198 patients  
with metastatic melanoma and renal cancer treated with anti-CTLA-4, 21% experienced Grade 3/4 
colitis [74], and the mortality in patients who developed autoimmune colitis due to bowel perforation 
was about 5% [75]. Enterocolitis has been linked to inflammatory bowel disease or graft-versus-host 
disease (GVHD) [74]. Indeed, it was suggested that common antigens expressed by tumor and bowel 
induces the T-cell infiltration. Another hypothesis is that enterocolitis was generated by cytokine 
production or dendritic cell activation by CD4 cells of autoimmune origin. 
The elevation of serum liver transaminases and/or bilirubin and inflammatory hepatitis ranges from 
2% to 9% across different studies [76]. Ipilimumab-induced hepatitis is rare, but can be life threatening. 
Finally, endocrinopathies, including hypophysitis, hypopituitarism, adrenal insufficiency, 
hypothyroidism or hypogonadism, were described in patients treated with ipilimumab and can require 
an accurate differential diagnosis with other causes [77]. 
Compared to anti-CTLA-4, agents targeting the PD-1/PD-L1 pathway seem to be better tolerated, 
with a more favorable toxicity profile, emphasizing the distinct biologic features of the two pathways.  
Toxins 2014, 6 924 
 
 
One reason that could explain the reduced toxicity could be that the PD1/PD-L1 checkpoint interaction 
takes place peripherally, i.e., at the tumor site, whereas the CTLA4/B7 interaction occurs mostly 
centrally, i.e., in the lymphoid organs [78]. Most of the toxicity associated with anti-PD-1/PD-L1  
was immune related, as well as with anti-CTLA-4 therapy [10,11]. The most frequent adverse  
events recorded, regardless of causality, were fatigue, decreased appetite, diarrhea, nausea, dyspnea, 
constipation, vomiting, rash, pyrexia and headache [10]. The Grade 3/4 adverse event rate was 14% in 
patients receiving nivolumab. Interestingly, one unique and potentially life-threatening toxicity for 
these agents is pneumonitis, which occurred in 3% of patients, but only 1%–3% developed a Grade 3 
or 4 pneumonitis [10,51,52]. No clear relationship was reported between the incidence of this side 
effect and tumor type, dose level or the number of doses received. In the majority of cases, it was 
reversible with treatment discontinuation and/or glucocorticoid administration, but three patients died 
despite the use of infliximab and mycophenolate [10]. Mild infusion reactions were observed in 
patients receiving anti-PD-L1 treatment, whereas severe adverse effects were infrequently noted [11]. 
Indeed, irAEs were observed in 39% of patients and included rash, hypothyroidism, hepatitis and, less 
frequently, sarcoidosis, diabetes mellitus and myasthenia gravis. These adverse events were 
predominantly of Grade 1 or 2 and were managed with treatment interruption or discontinuation. The 
Grade 3/4 adverse event rate was 9% in patients receiving BMS-936559 [49] and was managed with 
glucocorticoids. Table 2 summarizes the main serious adverse effects of checkpoint inhibitors. 
Table 2. Grade 3–4 serious adverse events of immune checkpoints inhibitors. 
Serious Adverse Events 
(Grade 3 and 4) 
Ipilimumab  
[9*,42,72,74,76] 
Tremelimumab 
[44–46] 
Anti-PD1 
(Nivolumab, 
Lambrolizumab) 
[3,51 **,52] 
Anti-PD-L1 
(BMS-936559) 
[4] 
Dermatologic 
Rash and/or pruritus 3.2%–4% 2.5%–18% 1%–4% <1% 
Gastrointestinal  
Diarrhea 4%–5.3% 5%–21% 1%–3% <1% 
Nausea or vomiting <5% 8%–13% 0 <1% 
Colitis 2%–21% 2.1%–18% 2%  
Endocrine  
Hypophysitis 0.8 2% 1% 0 
Hypothyroidism 0 1% 1% 0 
Hypopituitarism 0.8 1% Non reported 0 
Adrenal insufficiency 1.5 1% 0 <1% 
Hepatic 
Increase in alanine 
aminotransferase 1.5%–22% Not reported 1%–7% 0 
Increase in aspartate 
aminotransferase 0.8%–18% Not reported 1%–6% <1% 
Hepatitis <3% 1% Not reported <5% 
Fatigue 6%–10% 2%–13% 2% 3% 
Pneumonitis Not reported 1% 1%–3% Not reported 
Notes: * In this study, ipilimumab is in combination with dacarbazine; ** in this study, nivolumab is in 
combination with ipilimumab. 
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7. Toxicity of Other Immunomodulator Agents 
A Phase II clinical trial to assess the efficacy of anti-CD137 in melanoma patients was stopped due 
to severe side effects. The most common toxicities observed with this treatment were fatigue, 
transaminitis, neutropenia, rash and diarrhea [35]. Liver injury was the most frequent serious adverse 
event and, based on evidence from animal models, might be associated with increased liver CD8+ T-cell 
infiltration. Niu et al. demonstrated that CD137 agonist can induce immunologic alteration, resulting 
ultimately in toxicity in various organs, such as liver, lungs, spleen and bone marrow [79]. Indeed, 
CD137 receptor cross-linking, CD8+ T-cell and the production of TNF-α, IFN-γ and Type I IFN were 
crucial in inducing these side events. It is not known if T-cells are the direct targets of anti-CD137 
mAb or if they are indirectly influenced by either cytokines or chemokines produced by other lineages 
of CD137-expressing cells [80]. 
Nonetheless, the evidence that in absence of liver-infiltrating CD8+ T-cells or of TNF-α,  
anti-CD137 injected mice do not develop hepatitis supports the hypothesis that cytokine-induced 
inflammation was one of the causes of liver pathology. Thus, CD137-targeted immunostimulation, 
despite encouraging results with regard to immune responses, needs further evaluation to find a safer 
dosing with tolerable liver toxicity. 
The Phase I study that evaluated the safety and antitumor activity of dacetuzumab (anti-CD40 agent) 
in 44 patients with advanced multiple myeloma demonstrated that the treatment was generally well 
tolerated, and the most frequent adverse events potentially related to dacetuzumab were represented by 
cytokine release syndrome symptoms, non-infectious ocular inflammation and elevated hepatic 
enzymes [81]. These events were observed in 11%–16% of patients, and only 8% of them reported 
serious toxicity. A similar toxicity profile was observed in Phase I trials in patients with chronic 
lymphocytic leukemia and non-Hodgkin’s lymphoma [82,83]. The results of ongoing clinical trials are 
necessary to define the exact toxicity profile of this drug. 
Daclizumab, an anti-CD25 antibody, indicated in multiple sclerosis and to prevent rejection in 
organ transplantation, was studied in breast cancer patients with regard to human Treg survival and  
function. In this study, daclizumab, combined with an experimental cancer vaccine, led to a marked 
and prolonged decrease in Tregs in patients. Autoimmune reaction, although expected, was not 
observed in this study [84]. However, further studies are needed to evaluate the antitumor activity of 
this approach and related toxicities. 
8. Toxicity: Management and Correlation with Outcome 
The management of irAEs are based upon the severity of the observed toxicity and typically involve 
the early detection of toxicity, interruption of therapy, close clinical monitoring and early symptomatic 
relief. Not all irAEs will require permanent cessation of therapy. The primary treatment for most  
low-grade irAEs is supportive care, including oral hydration and loperamide for diarrhea, antipruritic 
medications or topical steroids for dermatologic lesions. Administration of systemic corticosteroids is 
required in the case of Grade 3–4 toxicities and is usually associated with the effective and rapid 
reversal of symptoms [30]. Despite the theoretical concern that corticosteroids or immunomodulators 
may blunt the antitumor effect of therapy, corticosteroids do not appear to affect the efficacy of  
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anti-CTLA-4 therapy, and antitumor activity continues to be recorded even in patients using  
steroids [85]. If symptoms persist despite high-dose steroids or are refractory to steroid tapering, other 
immunosuppressive treatments may be necessary, such as infliximab for severe enterocolitis [85]. 
Algorithms have been developed to aid in the management of these side effects and are available at the 
FDA Risk Elimination and Management System (REMS) website [86]. Utilizing these management 
strategies, life-threatening complications have been minimized. 
Interestingly, data derived from several early clinical trials suggested a possible relationship 
between irAEs and the clinical benefit of therapy, since patients who developed irAEs have shown a 
higher ratio of therapeutic response [85,87]. In a trial in which 56 Stage IV melanoma patients were 
treated with ipilimumab and a peptide vaccine, 36% of patients who had a severe irAE achieved a 
clinical response, whereas only 5% of patients without an irAE showed a response [88]. Similar results 
were observed in a double-blind, placebo-controlled Phase II study in which the response rate  
was higher in patients who experienced Grade 3/4 irAEs than in patients with Grade 0–2 irAEs [89]. 
Thus, the severity of irAE could be a surrogate marker of drug efficacy, even if the meaning of the 
relationship between the severity of irAEs and clinical response needs further confirmation to be 
considered definitive. 
9. Conclusions 
Breaking immune tolerance upon immune check point blockade may induce durable cancer 
proliferation control and, on the other hand, off target side effects affecting normal tissues as “innocent 
by-stander”. A better knowledge of the irAEs, as well as their management and prevention, is of 
enormous significance for a proper diagnosis and, accordingly, therapy. If a link between these AEs 
and specific immunotherapeutics is recognized, the withdrawal of therapy might be envisaged. 
A better understanding of the mechanisms of action of these drugs and of their interaction with  
the immune system and normal tissues might be useful to improve the toxicity profile with no impact 
on clinical response. 
Several questions are raised by all the data presented in this review article; the answer to these 
questions should be considered a possible area of research in the following years. Which patients 
should be treated with an immunotherapy approach? It is possible to predict the side effects developed 
during the course of immune-therapy? Is there any genetic signature predicting response to 
immunotherapy? What are the risks associated with such a treatment, i.e., the possibility of developing 
an autoimmune response? What is the durability of immune protection? Can we combine immune 
checkpoint blockade therapy with immunosuppressors to reduce side effects? Which are the optimal 
biological doses, schedules, methods of administration, timing and potential following boosts to 
maintain a durable immune response? Another important long-term concern for trials ongoing in the 
adjuvant setting is the potential induction of autoimmunity, which depends on the kind of tumor 
antigen that is targeted and the response that is elicited. Long-term follow up of these patients is a 
major issue. We need a better understanding of the relation between innate and adaptive immune 
responses and of the immune escape mechanisms employed by tumor cells, the discovery of the 
mechanisms underlying immunological tolerance and acknowledgment of the importance of both  
cell-mediated and humoral adaptive immunity for the control of tumor growth. What do we need going 
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forward to limit immune checkpoint blockade-induced toxicity? Most importantly, we need a better 
understanding of the roles played by these agents in normal tissues, so that we can begin to predict 
potentially problematic side effects on the basis of their selectivity profile. Second, we need to focus 
on the predictive factors of response and toxicity of the host rather than serially focusing on individual 
agents. Third, rigorous biomarker-driven clinical trials are needed to further elucidate the mechanisms 
of both the benefit and toxicity. 
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